P4LPrevention for LongevityEvidence → Decision → Adoption

Signal Radar · SIG-2026-002

FDA TEMPO participant page lists Dexcom only; prior Cadence expansion record withdrawn

FDA's current TEMPO participant table lists Dexcom, Inc. and the Dexcom Glucose Health Program as the selected participant. A prior P4L record stating that Cadence Solutions' HypertensionOS was also listed is withdrawn. CMS separately lists Cadence Health entities as ACCESS accepted applicants, but CMS states that accepted-applicant listing does not guarantee participation; it does not establish TEMPO participation.

100/100 priorityCorrection + Regulation + Digital HealthCorrected / current source reverified2026-08-11

Why it matters

The correction matters because ACCESS applicant status and TEMPO participant status are distinct program facts. P4L must reverify dynamic source tables and keep cross-program identity transfers from becoming downstream claims.

Decision implication

Use the FDA participant table—not ACCESS applicant status—to establish TEMPO participation, and reverify the table before consequential use.

Who or what is affected

  • FDA
  • CMS Innovation Center
  • Dexcom
  • Cadence Health ACCESS accepted applicants
  • ACCESS organizations

Evidence and sources

E5 — official federal source

P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.

What P4L is watching next

  • New FDA TEMPO participant additions
  • changes to intended uses
  • FDA participant-table changes
  • ACCESS applicant/participant status changes

Related proof records

Record provenance

Last verified
2026-08-11
Version
2.0
Stable ID
SIG-2026-002